These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 19450636

  • 21. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system.
    Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D.
    Vaccine; 2012 Mar 02; 30(11):2020-3. PubMed ID: 22361303
    [Abstract] [Full Text] [Related]

  • 22. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children.
    Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM.
    Pediatrics; 2005 Apr 02; 115(4):1039-47. PubMed ID: 15805382
    [Abstract] [Full Text] [Related]

  • 23. Emerging data on the safety and efficacy of influenza vaccines in children.
    Vesikari T.
    Pediatr Infect Dis J; 2008 Nov 02; 27(11 Suppl):S159-61. PubMed ID: 18955892
    [Abstract] [Full Text] [Related]

  • 24. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P, Moro PL, McNeil MM, Lewis P, Woo EJ, Hughes H, Shimabukuro TT.
    Vaccine; 2014 Nov 12; 32(48):6499-504. PubMed ID: 25258101
    [Abstract] [Full Text] [Related]

  • 25. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Haber P, Moro PL, Ng C, Dores GM, Lewis P, Cano M.
    Vaccine; 2019 Mar 07; 37(11):1516-1520. PubMed ID: 30739795
    [Abstract] [Full Text] [Related]

  • 26. Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults.
    Leeb A, Carcione D, Richmond PC, Jacoby P, Effler PV.
    Vaccine; 2011 Oct 19; 29(45):7920-4. PubMed ID: 21864621
    [Abstract] [Full Text] [Related]

  • 27. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
    Sever JL, Brenner AI, Gale AD, Lyle JM, Moulton LH, Ward BJ, West DJ.
    Pharmacoepidemiol Drug Saf; 2004 Dec 19; 13(12):825-40. PubMed ID: 15386719
    [Abstract] [Full Text] [Related]

  • 28. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.
    Vesikari T, Karvonen A, Smith HM, Dunning A, Razmpour A, Saville MK, Gruber WC, Forrest BD.
    Pediatrics; 2008 Mar 19; 121(3):e568-73. PubMed ID: 18299305
    [Abstract] [Full Text] [Related]

  • 29. Active SMS-based influenza vaccine safety surveillance in Australian children.
    Pillsbury A, Quinn H, Cashman P, Leeb A, Macartney K, AusVaxSafety consortium.
    Vaccine; 2017 Dec 18; 35(51):7101-7106. PubMed ID: 29128379
    [Abstract] [Full Text] [Related]

  • 30. Monitoring vaccine safety during an influenza pandemic.
    Iskander J, Haber P, Herrera G.
    Yale J Biol Med; 2005 Oct 18; 78(5):265-75. PubMed ID: 17132333
    [Abstract] [Full Text] [Related]

  • 31. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
    Sever JL, Brenner AI, Gale AD, Lyle JM, Moulton LH, West DJ, Anthrax Vaccine Export Committee.
    Pharmacoepidemiol Drug Saf; 2002 Oct 18; 11(3):189-202. PubMed ID: 12051118
    [Abstract] [Full Text] [Related]

  • 32. Post-Licensure Surveillance of Trivalent Live-Attenuated Influenza Vaccine in Children Aged 2-18 Years, Vaccine Adverse Event Reporting System, United States, July 2005-June 2012.
    Haber P, Moro PL, Cano M, Vellozzi C, Lewis P, Woo EJ, Broder K.
    J Pediatric Infect Dis Soc; 2015 Sep 18; 4(3):205-13. PubMed ID: 26407428
    [Abstract] [Full Text] [Related]

  • 33. Adverse events associated with intranasal influenza vaccine in the United States.
    Vasu N, Ghaffari G, Craig ET, Craig TJ.
    Ther Adv Respir Dis; 2008 Aug 18; 2(4):193-8. PubMed ID: 19124371
    [Abstract] [Full Text] [Related]

  • 34. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007.
    Niu MT, Ball R, Woo EJ, Burwen DR, Knippen M, Braun MM, VAERS Working Group.
    Vaccine; 2009 Jan 07; 27(2):290-7. PubMed ID: 18992783
    [Abstract] [Full Text] [Related]

  • 35. Administration of inactivated trivalent influenza vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Shah SI, Caprio M, Hendricks-Munoz K.
    Pediatrics; 2007 Sep 07; 120(3):e617-21. PubMed ID: 17766502
    [Abstract] [Full Text] [Related]

  • 36. The risk of fever following one dose of trivalent inactivated influenza vaccine in children aged ≥6 months to <36 months: a comparison of published and unpublished studies.
    Kaczmarek MC, Duong UT, Ware RS, Lambert SB, Kelly HA.
    Vaccine; 2013 Nov 04; 31(46):5359-65. PubMed ID: 24055353
    [Abstract] [Full Text] [Related]

  • 37. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.
    Ambrozaitis A, Groth N, Bugarini R, Sparacio V, Podda A, Lattanzi M.
    Vaccine; 2009 Oct 09; 27(43):6022-9. PubMed ID: 19666152
    [Abstract] [Full Text] [Related]

  • 38. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms.
    Blyth CC, Currie AJ, Wiertsema SP, Conway N, Kirkham LA, Fuery A, Mascaro F, Geelhoed GC, Richmond PC.
    Vaccine; 2011 Jul 18; 29(32):5107-13. PubMed ID: 21640152
    [Abstract] [Full Text] [Related]

  • 39. Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years.
    Schmidt-Ott R, Schwarz T, Haase R, Sander H, Walther U, Fourneau M, Htun-Myint L, Sänger R, Schuster V.
    Vaccine; 2007 Dec 21; 26(1):32-40. PubMed ID: 18022736
    [Abstract] [Full Text] [Related]

  • 40. Frequency of medically attended events following rapid revaccination with trivalent inactivated influenza vaccine.
    Schmidt MA, Crane B, Mullooly JP, Naleway AL.
    Vaccine; 2010 Nov 16; 28(49):7713-5. PubMed ID: 20875495
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.